Alternative Medicine News

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address the underlying causes of psychiatric and neurological disorders, today highlighted the advancement of its DT120 ODT (lysergide tartrate) clinical program and commercial strategy in major depressive disorder (MDD) and generalized anxiety disorder (GAD), with three anticipated topline re...

LOUISVILLE, Ky.--(BUSINESS WIRE)--Cornbread Hemp, the premium wellness brand known for its commitment to clean, USDA-certified organic hemp products, today announced the launch of its first-ever non-hemp functional wellness line: Cornbread Relax Mushroom Gummies, Cornbread Focus Mushroom Gummies, and Cornbread Sleep Mushroom Gummies. All three products will be available nationwide at cornbreadhemp.com, with shipping to all 50 states and US territories. This launch represents a major expansion o...

BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the metabolic health and wellness company known for its science-backed, coach-guided lifestyle system, will announce financial results for the quarter ended March 31, 2026 on Monday, May 4, 2026, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, Nick Johnson, President, and Jim Maloney, Chief Financ...

CORALVILLE, Iowa--(BUSINESS WIRE)--IDT's synthesis capacity is increasing by threefold to support faster, scalable, and highly customized oligonucleotide production for MRD and NGS....

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (OTCID: ALUR), a pioneer in metabolically healthy weight loss, today announced the successful commercial treatment of its first patients in the United States—an inflection point that formally launches the company into the world’s largest and most dynamic obesity market. Allurion is seeing growing demand from patients who have discontinued GLP-1 therapy due to side effects, long-term commitment concerns, or weight regain following disco...

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that CEO Kabir Nath will participate in a panel entitled “Clinical Risk, Regulatory Reality and the Path to Scale” at the Needham Virtual Psychedelics Forum on April 27, 2026, at 11am-12pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of...

CHICAGO--(BUSINESS WIRE)--The postponement of Blue Cross Blue Shield of Michigan’s (BCBSM) proposed reimbursement policy affecting evaluation and management (E/M) services billed with modifier 25 marks a critical step in safeguarding accurate physician reimbursement, reducing administrative burden and protecting patient access to timely, high-quality care. The decision, announced April 15, follows significant feedback from osteopathic physicians and organized medicine regarding the policy’s ope...

OTTAWA, Ontario--(BUSINESS WIRE)--Fullscript, a provider-led health platform doing over $1B in revenue annually, used by more than 125,000 healthcare providers and more than 5 million patients annually across North America, today announced the general availability of Fullscript Journeys, a new product that gives practitioners the technology to deliver modern, consumer-grade health experiences while keeping clinical guidance at the center of care. With journeys, Fullscript is taking the Shopify...

TORONTO & BERLIN--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”) and Sanity Group GmbH (“Sanity” or “Sanity Group”) jointly announced the successful closing of Organigram’s previously announced acquisition (the “Acquisition”) of Sanity Group, pursuant to the terms of a share purchase agreement dated February 18, 2026 (the “Share Purchase Agreement”). In connection with closing of the Acquisition, a wholly owned subsidiary of the Company acquire...

NEWCASTLE, England--(BUSINESS WIRE)--Atelerix, a biotech company revolutionising cell preservation and biological transport with its pioneering hydrogel encapsulation technology, today announced it has established a strategic partnership with JH Health Ltd, a Saudi Arabian company focused on medical and health-related technology. The partnership grants JH Health exclusive rights to use and distribute Atelerix’s hydrogel-based cell and tissue preservation solutions in the Middle East, significan...